Ispire Technology Inc. (Nasdaq: ISPR) Q4 2025 Earnings Call | 09/16/2025

Summary of Ispire Technology Inc. Q4 and Full Year 2025 Earnings Call (9/16/2025)

Overview: Ispire Technology Inc., a leader in vaping technology and precision dosing, held its Q4 and FY 2025 earnings call on September 16, 2025, hosted by Phil Carlson (KCSA Strategic Communications), with Co-CEO Michael Wang and CFO Jay Yu. The call reviewed financial results for the fiscal year ended June 30, 2025, and outlined strategic shifts toward the nicotine sector, cost optimization, and regulatory advancements.

Financial Performance:

• Fiscal Year 2025:
  • Revenue: $127.5 million, down from $151.9 million in FY 2024, due to a strategic pivot away from cannabis toward nicotine.
  • Gross Profit: $22.7 million, down from $29.8 million, with gross margin at 17.8% (vs. 19.6% in FY 2024), reflecting the shift in product mix.
  • Operating Expenses: Increased to $60.5 million from $43.7 million, driven by higher sales/marketing and bad debt expenses, partially offset by lower stock-based compensation and R&D costs.
  • Net Loss: Widened to $39.2 million from $14.8 million in FY 2024.
  • Accounts Receivable: Reduced by 21% year-over-year to $47.0 million from $59.7 million, and by 9.1% ($6.9 million) from Q3 to Q4 2025.
  • General & Administrative Expenses: Decreased from $7.6 million in Q3 to $6.7 million in Q4 2025.
  • Cash Position: $24.4 million, down $10.7 million from FY 2024, with working capital at $0.4 million.
  • Cash Flow: Net cash used in operating activities improved to $7.4 million from $18.3 million; investing activities used $5.2 million (vs. $3 million provided in FY 2024); financing activities provided $1.9 million (vs. $10.1 million used in FY 2024).
• Q4 2025:
  • Revenue: $20.14 million, down from $37.34 million in Q4 2024, missing estimates by 10.1%.
  • EPS: -$0.69, missing forecasts of $0.18 profit, a negative surprise of 483.33%.
  • Bad Debt Provision: $22 million, reflecting cumulative issues across multiple customers, not a single client.

Geographic Revenue:

• Europe: $74.1 million, up 13.6% from $65.3 million in FY 2024.
• North America: $32.6 million, down from $63.1 million, due to reduced cannabis focus.
• Asia Pacific: $12.3 million, down from $17.6 million.
• Other Countries (mainly South Africa): $8.5 million, up from $6 million.

Strategic Highlights:

• Pivot to Nicotine: Ispire shifted focus from cannabis to the higher-value nicotine sector, prioritizing sustainable, long-term growth over short-term revenue. This led to a revenue decline but improved financial stability through better customer quality and payment terms.
• Cost Optimization: Reduced annual expenses by $10.2 million, with ongoing efforts to lower fixed costs and streamline operations. General and administrative expenses dropped in Q4, and accounts receivable decreased significantly.
• Malaysian Manufacturing: Expanded production capacity, operating six lines with plans for up to 80. A second facility is being modified, and a third, larger facility is under consideration to meet global demand and diversify supply chains amid geopolitical shifts.
• Regulatory Progress: Advancing PMTA submissions, including a groundbreaking blockchain-based age-gating technology (iCag) via IEC Tech LLC. The FDA accepted the component PMTA in four weeks, an unprecedented speed, with a potential deficiency letter expected (timeline unclear, possibly 3 months to over a year). This technology could enable modular deployment across numerous ENDS products.
• ODM Business: International nicotine ODM business gained momentum, with an $18 million revenue pipeline, particularly from a UK client where an upgraded product (version two) launched successfully in summer 2025. New iterations are planned by year-end.
• IP Protection: Secured patents in the US, EU, UK, and China for age-gating and G-Mesh technologies, focusing on device-app communication and blockchain-based data processing to ensure defensibility.
• Leadership: Appointed Jay Yu as CFO in May 2025, leveraging his public company accounting experience and operational knowledge.

Q&A Highlights:

• Age-Gating Technology: The FDA’s rapid acceptance of the component PMTA is encouraging, with global interest from regulators in at least two undisclosed countries moving faster than the US. The technology’s blockchain-based, real-time authentication sets it apart from traditional systems.
• Cannabis Pivot: The US cannabis market ($30 billion, with vaping ~25%) remains promising, but cash flow challenges due to lack of federal legalization and banking services prompted Ispire’s pivot. Q4 2025 was the revenue bottom, with new, higher-quality cannabis customers and products planned. Rescheduling could prompt reevaluation of cannabis investments.
• UK ODM Agreement: Version two of the product addressed market dynamics post-UK disposable vape bans, with strong initial feedback and an $18 million backlog. Further iterations are in development to maintain competitiveness.
• Tariff and Supply Chain: Increased interest from brands diversifying away from China due to tariffs. Ispire’s Malaysian facilities position it to capture these opportunities, with expansion plans tied to regulatory approvals.